Skip to main content

  • Responding to COVID‐19: How to Navigate a Public Health Emergency Legally and Ethically

    31 Mar, 2020
    AbstractFew novel or emerging infectious diseases have posed such vital ethical challenges so quickly and dramatically as the novel coronavirus SARS‐CoV‐2. The World Health Organization declared a public health emergency of international concern and recently classified COVID‐19 as a worldwide pandemic. As of this writing, the epidemic has not yet peaked in the United States, but community transmission is widespread. President Trump declared a national emergency as fifty governors declared sta...
  • Lockdowns in Europe could have averted tens of thousands of deaths

    31 Mar, 2020
    The infection-control measures put in place in many European countries – such as national lockdowns – are reducing the spread of the coronavirus. Across 11 countries in Western and Northern Europe, between 21,000 and 120,000 deaths will probably have been avoided by the end of March, according to a new model by a group at Imperial College London. The study, published by the Imperial College COVID-19 Response Team on 30 March, estimates the effects that non-pharmaceutical interventio...
  • Estimates of the severity of coronavirus disease 2019: a model-based analysis

    31 Mar, 2020
    As of March 25, 2020, 414 179 cases and 18 440 deaths due to coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had been reported worldwide. The epidemic began in mainland China, with a geographical focus in the city of Wuhan, Hubei. However, on Feb 26, 2020, the rate of increase in cases became greater in the rest of the world than inside China. Substantial outbreaks are occurring in Italy (69 176 cases), the USA (51 91...
  • Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

    30 Mar, 2020
    Could administration of convalescent plasma transfusion be beneficial in the treatment of critically ill patients with coronavirus disease 2019 (COVID-19)?
    In this uncontrolled case series of 5 critically ill patients with COVID-19 and acute respiratory distress syndrome (ARDS), administration of convalescent plasma containing neutralizing antibody was followed by an improvement in clinical status.
    These preliminary findings raise the possibility that convalescent plasma transfusion may...
  • Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia

    30 Mar, 2020

    Pregnant women infected with Covid-19 were evaluated to provide future help for clinical prevention and treatment. All the cases were from Hospital of Hubei Province and had the gestational week from 38th weeks to 41th weeks. Their primary initial manifestations were merely low-grade postpartum fever or mild respiratory symptoms. 

    As a conclusion, these doctors stated that the protective measures are necessary on admission, and the instant CT scan and ...
  • Clinical and virological data of the first cases of COVID-19 in Europe: a case series

    30 Mar, 2020
    The coronavirus disease 2019 (COVID-19) epidemic spread within China, and secondarily also outside China, with a basic reproductive number estimated to be from to and a mortality rate of around 2-3%. In the EU (and European Economic Area) and the UK, as of March 6, 2020, 5544 cases have been reported (423 in France), including 159 deaths (seven in France).
    So far, several studies have described demographic, clinical, and biological characteristics of patients with COVID-19, ...
  • COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal

    29 Mar, 2020

    COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal.Hasan K. Siddiqi, MD, MSCR, and Mandeep R. Mehra, MD, MSc The journal of heart and lung transplantation has prepared a clinical-therapeutic staging proposal about management of patients with Inmunosuppresed state

  • COVID-19 in a patient with chronic lymphocytic leukaemia

    29 Mar, 2020
    Since the outbreak of coronavirus disease 2019 (COVID-19) first began in Wuhan, China, in December, 2019, the viral epidemic has quickly engulfed China. Here we describe a case of a patient with chronic lymphocytic leukaemia with COVID-19.

    In conclusion, clinical and biochemical data of COVID-19 might be partly masked by coexisting chronic lymphocytic leukaemia; better diagnostic strategies (ie, superior CT differential techniques such as radiomics) could be used f...
  • Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang

    28 Mar, 2020

    Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort studyA cohort study of 44 672 Chinese cases reported that 2·1% of patients were younger than 20 years, and 1·2% were asymptomatic. Pneumonia is the leading cause of mortality in children.8 Distinct immunological responses to viral infections can exist in children and result in severe damage to vital organsTo read full text ...
  • Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

    27 Mar, 2020
    In this cohort study of 416 consecutive patients with confirmed COVID-19, cardiac injury occurred in 19.7% of patients during hospitalization, and it was one independent risk factor for in-hospital mortality.Cardiac injury is a common condition among patients hospitalized with COVID-19, and it is associated with higher risk of in-hospital mortality.

    To explore the association between cardiac injury and mortality in patients with COVID-19.

    Design, Setti...
  • Nature publishes: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

    27 Mar, 2020

    Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2Abstract

    Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, c...
  • COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission

    26 Mar, 2020
    Current studies reveal that respiratory symptoms of COVID-19 such as fever, dry cough, even dyspnea represent the most common manifestations at visit similar to severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012, which is firmly indicative of droplet transmission and contact transmission. However, the incidence of less common features like diarrhea, nausea, vomiting and abdominal discomfort varies significantly among different study popu...